Autolus: Autolus Therapeutics plc: Autolus Therapeutics Announces License of AUCATZYL (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (= 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia ...
UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA u...
Read full article »
Autolus is a biopharmaceutical company that develops and commercializes T-cell immunotherapies for the treatment of cancer.
Read more